Ptx to 10 bag by this time next year, page-11

Shellbell, I think you nailed it with your latest post. My read on this (IMO) PTX licensed OmniCar with a strong desire to licence to many (why would a tiny company like PTX get the exclusivity if there was an expectation by Penn that we would simply on-sell the rights), monetise and then possibly share the proceeds with some of the aligned parters (Peter Mac, etc., ) to keep the research moving forward, and then feeding that back into our pipeline. This way the creators of OmniCar can be assured the technology will benefit as many people as possible, rather than one large pharma that controls how it’s used (i.e. not shared or shelved).

I’m still a believer in PTX100 as it’s what kept me engaged many years ago, and I think we will have something really tangible around by une next year (i.e. enrolments by end of September + 2 x Avg survival time of 4-months if a high percentage of the enrolled patients have a high efficacy). All just my own opinions of course.

I’ve also been wondering if the stealth projects somehow tie the PTX100/200 programs with OmniCar….again pure speculation of course.

GLTAH - Patience is a virtue here as I’ve had to learn in spades holding and accumulating PTX